A Phase 3 interventional study of Ofloxacin and Avelox (Moxifloxacin, BAY12-8039) in Pelvic Inflammatory Disease, sponsored by Bayer. Completed at 77 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-15.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Comparison of various antibiotics in treatment of uncomplicated pelvic inflammatory disease
34 studies on the registry are indexed under Pelvic Inflammatory Disease; 4 are open to participants now.
This study's enrollment of 749 is above the median of 143 across 26 interventional studies indexed under Pelvic Inflammatory Disease.
Browse Pelvic Inflammatory Disease studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ofloxacin
Drug: Avelox (Moxifloxacin, BAY12-8039)
Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
Moxifloxacin 400 mg po od for 14 days
Clinical response 5 to 24 days after the last dose of study medication
Time frame: 5 to 24 days after the last dose
Bacterial response at the test of cure visit and at the FU visit 28 to 42 days after last dose of study medication
Time frame: visit 28 to 42 days after last dose
Clinical response at during-treatment visit (Day 4-7) and at follow-up 28 to 42 days after last dose
Time frame: (Day 4-7) and at follow-up 28 to 42 days after last dose
Reduction from baseline in pain report at the different assessment visits
Time frame: Over the entire trial period (overall)
Necessity for modifying antibiotic therapy at the during-treatment visit and TOC visit and necessity for institution of an antibiotic therapy at follow-up
Time frame: Over the entire trial period (overall)
The record gives a start of Apr 2003, a primary completion of Oct 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin